{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:08:28Z","timestamp":1792278508657,"version":"4.4.0"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information approved by the FDA provides helpful guidelines but does not address practical questions that are being raised by nephrologists, internists, and general practitioners taking care of patients with ADPKD, and by the patients themselves. In this review, we provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively. These steps include confirmation of diagnosis; identification of rapidly progressive disease; implementation of basic renal protective measures; counseling of patients on potential benefits and harms; exclusions to use; education of patients on aquaresis and its expected consequences; initiation, titration, and optimization of tolvaptan treatment; prevention of aquaresis-related complications; evaluation and management of liver enzyme elevations; and monitoring of treatment efficacy. Our recommendations are made on the basis of published evidence and our collective experiences during the randomized, clinical trials and open-label extension studies of tolvaptan in ADPKD.<\/jats:p>","DOI":"10.1681\/asn.2018060590","type":"journal-article","created":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T11:58:33Z","timestamp":1537271913000},"page":"2458-2470","source":"Crossref","is-referenced-by-count":246,"title":["A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan"],"prefix":"10.1681","volume":"29","author":[{"given":"Fouad T.","family":"Chebib","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene B.","family":"Chapman","sequence":"additional","affiliation":[{"name":"Section of Nephrology, University of Chicago School of Medicine, Chicago, Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[{"name":"Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5304-6593","authenticated-orcid":false,"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mrug","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Veterans Affairs Medical Center and University of Alabama, Birmingham, Alabama;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem A.","family":"Mustafa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of California, Los Angeles, Los Angeles, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Watnick","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.L.","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension and the Kidney Institute, University of Kansas Medical Center, Kansas City, Kansas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"key":"B1-20230829","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B2-20230829","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"B3-20230829","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/ndt\/gfx079","article-title":"Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 Trial","volume":"32","author":"Torres","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B4-20230829","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2215\/CJN.01520218","article-title":"Long-term administration of tolvaptan in autosomal dominant polycystic kidney disease","volume":"13","author":"Edwards","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5-20230829","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"B6-20230829","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: The changing face of clinical management","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"key":"B7-20230829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B8-20230829","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B9-20230829","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1681\/ASN.2014030297","article-title":"Imaging-based diagnosis of autosomal dominant polycystic kidney disease","volume":"26","author":"Pei","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230829","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B11-20230829","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1172\/JCI90129","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"key":"B12-20230829","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ajkd.2017.11.015","article-title":"The value of genetic testing in polycystic kidney diseases illustrated by a family with PKD2 and COL4A1 mutations","volume":"72","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B13-20230829","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7326\/L17-0644","article-title":"Genomic analysis to avoid misdiagnosis of adults with bilateral renal cysts","volume":"169","author":"Gulati","year":"2018","journal-title":"Ann Intern Med"},{"key":"B14-20230829","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B15-20230829"},{"key":"B16-20230829","doi-asserted-by":"crossref","first-page":"2054358117695784","DOI":"10.1177\/2054358117695784","article-title":"Assessing risk of disease progression and pharmacological management of autosomal dominant polycystic kidney disease: A Canadian expert consensus","volume":"4","author":"Soroka","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"B17-20230829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B18-20230829","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"B19-20230829","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20230829","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","article-title":"Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease","volume":"93","author":"Yu","year":"2018","journal-title":"Kidney Int"},{"key":"B21-20230829","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/j.ajkd.2015.04.044","article-title":"Therapeutic area data standards for autosomal dominant polycystic kidney disease: A report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC)","volume":"66","author":"Perrone","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B22-20230829","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B23-20230829","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: A simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B24-20230829","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: The HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B25-20230829","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12882-017-0654-y","article-title":"Temporal and geographical external validation study and extension of the Mayo Clinic prediction model to predict eGFR in the younger population of Swiss ADPKD patients","volume":"18","author":"Girardat-Rotar","year":"2017","journal-title":"BMC Nephrol"},{"key":"B26-20230829","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: The TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"key":"B27-20230829","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","article-title":"Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: The Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)","volume":"46","author":"O\u2019Neill","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B28-20230829","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/ki.2015.71","article-title":"A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease","volume":"88","author":"Bhutani","year":"2015","journal-title":"Kidney Int"},{"key":"B29-20230829","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10278-017-9978-1","article-title":"Performance of an artificial multi-observer deep neural network for fully automated segmentation of polycystic kidneys","volume":"30","author":"Kline","year":"2017","journal-title":"J Digit Imaging"},{"key":"B30-20230829","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2214\/AJR.15.15875","article-title":"Semiautomated segmentation of polycystic kidneys in T2-weighted MR images","volume":"207","author":"Kline","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"B31-20230829","article-title":"Standardizing total kidney volume measurements for clinical trials of ADPKD","author":"Edwards","journal-title":"Am J Nephrol"},{"key":"B32-20230829","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B33-20230829","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B34-20230829","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/01.ASN.0000013300.11876.37","article-title":"The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease","volume":"13","author":"Rossetti","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B35-20230829","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1097\/01.ASN.0000061774.90975.25","article-title":"Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease","volume":"14","author":"Magistroni","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B36-20230829","article-title":"Recent advances in the management of autosomal dominant polycystic kidney disease [published online ahead of print July 26, 2018]","author":"Chebib","journal-title":"Clin J Am Soc Nephrol"},{"key":"B38-20230829","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"B39-20230829","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"B40-20230829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/toxsci\/kfw193","article-title":"Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors","volume":"155","author":"Woodhead","year":"2017","journal-title":"Toxicol Sci"},{"key":"B42-20230829","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12882-018-0957-7","article-title":"Case report: A thiazide diuretic to treat polyuria induced by tolvaptan","volume":"19","author":"Kramers","year":"2018","journal-title":"BMC Nephrol"},{"key":"B43-20230829","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1681\/ASN.2004121079","article-title":"Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans","volume":"16","author":"Bankir","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B44-20230829","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00424-017-2002-2","article-title":"Regulation of renal Na-(K)-Cl cotransporters by vasopressin","volume":"469","author":"Bachmann","year":"2017","journal-title":"Pflugers Arch"},{"key":"B45-20230829","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: Results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B46-20230829","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1124\/jpet.114.213256","article-title":"Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury","volume":"349","author":"Aihara","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"B47-20230829","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B48-20230829","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: Three years\u2019 experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B49-20230829","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: Phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B50-20230829","author":"Gansevoort"},{"key":"B51-20230829","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3899\/jrheum.160452","article-title":"Serum uric acid and the risk of incident and recurrent gout: A systematic review","volume":"44","author":"Shiozawa","year":"2017","journal-title":"J Rheumatol"},{"key":"B52-20230829","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2017.12.009","article-title":"Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: Report of a scientific workshop organized by the national kidney foundation","volume":"71","author":"Johnson","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B53-20230829","first-page":"CD009460","article-title":"Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease","volume":"10","author":"Sampson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B54-20230829","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1053\/j.ajkd.2016.07.023","article-title":"Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: A pilot randomized controlled trial","volume":"68","author":"Amro","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B55-20230829","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","article-title":"Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A new health-related quality-of-life instrument","volume":"71","author":"Oberdhan","year":"2018","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201810000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:32:02Z","timestamp":1786131122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201810000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2018060590","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734041313.793555210","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.734041313.793555520","asserted-by":"object"}]},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]}}}